Elicera Therapeutics AB Cash Flow-to-Debt Ratio
Elicera Therapeutics AB cash flow-to-debt ratio. Elicera Therapeutics AB (ELIC) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of Skr-4.74 Million could theoretically repay -1% of its total liabilities (Skr6.97 Million) in one year. Check how high is Elicera Therapeutics AB's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Elicera Therapeutics AB (2017–2024)
Cash flow-to-debt ratio of Elicera Therapeutics AB from 2017 to 2024. Historical debt coverage capacity for Elicera Therapeutics AB across 8 annual periods. Check ELIC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Elicera Therapeutics AB Cash Flow-to-Debt Ratio by Year (2017–2024)
Elicera Therapeutics AB cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Elicera Therapeutics AB. For the full cash flow conversion analysis, see ELIC cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.45x | Skr-23.46 Million | Skr6.79 Million | ▼ -219.0% |
| 2023 | -1.08x | Skr-14.92 Million | Skr13.78 Million | ▼ -70.7% |
| 2022 | -0.63x | Skr-8.57 Million | Skr13.51 Million | ▲ +88.9% |
| 2021 | -5.72x | Skr-14.29 Million | Skr2.50 Million | ▼ -1386.4% |
| 2020 | -0.38x | Skr-905.25K | Skr2.35 Million | ▲ +99.4% |
| 2019 | -59.79x | Skr-239.16K | Skr4.00K | ▲ +0.0% |
| 2018 | -59.79x | Skr-239.16K | Skr4.00K | ▲ +0.0% |
| 2017 | -59.79x | Skr-239.16K | Skr4.00K | — |